Abstract
Circulating insulin antibodies (CIA) were measured in two patients treated with continuous subcutaneous infusion (CSII) of human insulin (recombinant DNA). CIA were determined by a kinetic equilibrium assay after pretreatment of the serum to remove bound and free insulin. We observed that by changing from either purified bovine or purified porcine insulin to human insulin given by CSII, there is a gradual decrease in CIA detectable after 3 wk and more pronounced 3 mo after changing. These findings suggest that human insulin in combination with the improved metabolic control by CSII considerably reduces the antibody formation in patients with IDDM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
